Beyond the single-drug approval, the FDA’s action ties Veppanu access to ESR1 mutation identification, pulling molecular diagnostics further into the center of clinical workflow. Guardant Health’s companion diagnostic efforts support patient selection across tissue and liquid biopsy approaches, enabling targeted use rather than broader trial-indication adoption. For the biotech sector, the development is a reminder that PROTAC differentiation is increasingly evaluated through biomarker-delimited response patterns and diagnostic gatekeeping. Companies building “smart” degradation programs are also likely to plan development around assay reliability and repeatability. The result is an approval that expands the ER-degradation menu while concentrating real-world prescribing on a narrow molecular slice of breast cancer patients.